Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

Hervé Avet-Loiseau,Jean Soulier,J.P. Fermand,I. Yakoub-Agha,M Attal,C. Hulin,Laurent Garderet,Karim Belhadj,Véronique Dorvaux,Stephane Minvielle,P. Moreau

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.

2010

Hervé Avet-Loiseau
Jean Soulier
J.P. Fermand
I. Yakoub-Agha
M Attal
C. Hulin
Laurent Garderet
Karim Belhadj
Véronique Dorvaux
Stephane Minvielle
P. Moreau

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone

Keywords:

Dexamethasone
Cancer research
Corticosteroid
Cancer
Prior Therapy
Lenalidomide
Hematology
Oncology
Surgery
Medicine
Chemotherapy
Internal medicine
Cytogenetics
Thalidomide
Bortezomib
Refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

132

Citations